The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate Cancer

Clinical Pearls

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

• The primary aim of this study was to show a 10% reduction in prostate cancer mortality
• The final analysis (median follow-up of 11 years) showed about an 11% reduction in prostate cancer-specific mortality
• The benefit could have been even greater, as elderly men die of other causes which cannot be affected by treatment, such as cardiovascular disease